{
    "clinical_study": {
        "@rank": "1413", 
        "arm_group": {
            "arm_group_label": "Radiolabeled Prucalopride Succinate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Phase I study to evaluate the excretion of radioactivity, the metabolic profile,\n      pharmacokinetics, safety and tolerability following a single oral administration of [14C]\n      Prucalopride Succinate in healthy male volunteers aged 18 to 50 years (inclusive).The\n      purpose of this study is to investigate how and how quickly Prucalopride Succinate or its\n      break down products are excreted by analysing blood, faeces and urine samples collected\n      during the study."
        }, 
        "brief_title": "Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males aged between 18 and 50 years, inclusive\n\n          -  Body mass index (BMI) of \u226518 and \u226430 kg/m2\n\n          -  No more than 2 bowel movements per day or fewer than 3 bowel movement per week\n\n          -  Provision of signed and dated, written informed consent prior to any study specific\n             procedures\n\n        Exclusion Criteria:\n\n          -  Have participated in a [14C]-study within the last 6 months.\n\n          -  Exposure to clinically significant radiation within 12 months prior to dose (for\n             example, serial X-ray or computed tomography scans, barium meal, current employment\n             in a job requiring radiation exposure monitoring).\n\n          -  Male subjects who consume more than 21 units of alcohol per week or 3 units per day."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807000", 
            "org_study_id": "SPD555-104"
        }, 
        "intervention": {
            "arm_group_label": "Radiolabeled Prucalopride Succinate", 
            "description": "A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.", 
            "intervention_name": "Radiolabeled Prucalopride Succinate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Covance Global Clinical Research Unit Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Prucalopride Succinate Following a Single Oral Dose in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Covance Clinical Research Center Inc.", 
            "last_name": "Stephen Flach", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Total Radioactivity in whole blood of Radiolabeled Prucalopride Succinate", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }, 
            {
                "measure": "Total Radioactivity in plasma of Radiolabeled Prucalopride Succinate", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }, 
            {
                "measure": "Total Radioactivity in urine of Radiolabeled Prucalopride Succinate", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }, 
            {
                "measure": "Total Radioactivity in stool of Radiolabeled Prucalopride Succinate", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }, 
            {
                "measure": "Area Under the Plasma Concentration Versus Time Curve (AUC) of Radiolabeled Prucalopride Succinate", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of Radiolabeled Prucalopride Succinate", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }, 
            {
                "measure": "Identify and Quantify Metabolites of Radiolabeled Prucalopride Succinate  recovered in plasma, urine and stool", 
                "safety_issue": "No", 
                "time_frame": "collected over 10 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807000"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Shire", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}